Suche klinische Studie
Weitere Suchoptionen
174 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STRONGTREAT: Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis - ES (Completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Phase III-Studie zur Einschätzung der klinischen Wirksamkeit und Sicherheit des polyclonalen Anti- Pseudomonas-Antikörpers IgY zur Vermeidung des Wiederauftretens einer Pseudomonas Aeruginosa-Infektion bei Patienten mit zystischer Fibrose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors (PRECARDIA)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis (Phase II) - ES (Completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNy) Monoclonal Antibody, in Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis which has Reactivated - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophy - UK (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - SK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody (Phase II) - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MABSOT: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - BE (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene, einarmige, multizentrische Pilot-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit der mehrfach intravenöser Gabe von NI-0501, einem monoklonalen Anti-Interferon-Gamma (Anti-IFNy) Antikörper, bei pädiatrischen Patienten mit reaktivierter primären hämophagozytischen Lymphohistiozytose (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine Phase II-Studie des tumorspezifischen menschlichen Fusionsproteins monoklonalen Zytokin-Antikörpers F16IL2 in Kombination mit Paclitaxel versus Paclitaxel allein bei Patienten mit metastatischem Merkelzellkarzinom - DE -completed-
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Study of the safety and preliminar effectiveness of infused allogeneic mesenchymal stem cells (MSC) derived from adipose tissue in patients with Recessive Dystrophic Epidermolysis Bullosa (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis- IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NEUROSIS Ť Neonatal European Study of Inhaled Steroids ť: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - Phase III - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEREST study: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DietINT: A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP08: Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MesaCapp: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (Phase 2) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) - US
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Langzeit-Follow-up der Sicherheit und biochemischen Krankheitskontrolle von InfacortŽ bei Neugeborenen, Säuglingen und Kindern mit angeborener Nebennierenhyperplasie und Nebenniereninsuffizienz, die zuvor in die Infacort 003-Studie aufgenommen wurden
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
JIKI: Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Offene, langfristige Extensionsbehandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der IEDAT-02-2015-Studie teilgenommen haben -DE-
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia (Phase III) - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (Phase III) - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea (Ebola-Tx) (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Subjects Affected by Acanthamoeba Keratitis - PL
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MIROCALS : Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM : A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomisierte, doppelblinde, Placebo-kontrollierte, Dosis-Eskalationsstudie zur Beurteilung der Sicherheit, Verträglichkeit und Pharmakokinetik von QR-010 bei CF-Patienten mit homozygoter deltaF508-Mutation
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
The "DeSScipher" Project - to Decipher the Best Treatment for Systemic Sclerosis - Observational Trial 2: Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the delta F508 CFTR Mutation (Phase I) - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine explorative klinische Studie von Patienten in der frühen Phase der Huntington-Krankheit zur Beurteilung der Pharmakokinetik, der pharmakodynamischen Messungen des Zieleingriffs und der Krankheitsmodulation sowie der akuten phänotypischen Effekte nach mehreren oralen Dosen von SEN0014196
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD - A double-blind, parallel group study - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GANNET53: A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomisierte kontrollierte Studie (RCT) zur Bestimmung der Wirksamkeit und Sicherheit der Erhaltungstherapie mit Azithromycin (AZN) für 6 Monate bei Patienten mit PCD - Eine doppelblinde, parallele Gruppenstudie.
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment with Niraparib versus Ganetespib plus Carboplatin in platinum-sensitive ovarian cancer patients - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Eine Phase-I/II-Studie mit IMA970A plus CV8102 nach einer einzigen Präimpf-Infusion von Cyclophosphamid bei Patienten mit einem sehr frühen, frühen und mittleren Stadium des hepatozellulären Karzinoms nach allen Standardbehandlungen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLIOMARK1: Exploratorische Phase II-Studie bei Patienten nach Behandlung eines hochgradigen Hirntumors zur Beurteilung des Stellenwerts von Tc-99m Tetrofosmin bei der Differenzierung zwischen Rezidiv und Strahlennekrose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Treg Therapy: Therapie der Steroid-refraktären chronischen Graft-versus-Host-Erkrankung mit regulatorischen Spender-T-Zellen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NISCI: Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial - CH
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (Phase 1)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ENALONG: Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP09: Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapie: Eine offene Phase I/IIa-Studie zur Wiederverwendung von Carbamazepin (CBZ) für die Behandlung von Skelettdysplasien bei Kindern
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: Internationale randomisierte kontrollierte Studie zur Chemotherapie für die Behandlung von rezidivierenden und primären refraktären Ewing-Sarkomen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Offene, langfristige, verlängerte Behandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der Studie IEDAT-02-2015 teilgenommen haben
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Sicherheit und Wirksamkeit von TUDCA als Zusatztherapie bei ALS-Patienten
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: Eine internationale, multizentrische, randomisierte, kontrollierte Phase III-Studie zur Evaluation von Mirtazapin zur Linderung von Atemnot in Palliative Care
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1 : Eine klinische Studie der Phase I/IIa zur Beurteilung der Durchführbarkeit, Sicherheit und Antitumoraktivität von autologen SLAMF7 CAR-T-Zellen beim Multiplen Myelom
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1: A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients - BE
European Commission
DG Research - Directorate General for Research
Multinationale klinische Studie(n)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STRONGTREAT: Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis (Coordination)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GENEGRAFT: Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (Orphan drug designation (EU/3/09/630))
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT: Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSARC: European Clinical trials in Rare Sarcomas within an integrated translational trial network
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TAIN: Treatment of Adrenal Insufficiency in neonates- Development of a Hydrocortisone Preparation for the treatment of Adrenal Insufficiency in neonatesand infants
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
FIGHT-HLH: First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GAPVAC: Konsortium für die Entwicklung aktiv personalisierter Impfstoffe gegen Gliome
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DEVELOPAKURE: Clinical Development of Nitisinone for Alkaptonuria
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROFANCOLEN: Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TRAUMAKINE: Interferon-beta treatment of acute respiratory distress syndrome (ARDS)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MeuSIX: Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SKIP-NMD: A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ELIMOX: Biopharmaceutical therapy for treatment of Primary Hyperoxaluria
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ODAK: Orphan drug for Acanthamoeba Keratitis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EURO EWING Consortium - International Clinical Trials to Improve Survival from Ewing Sarcoma
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CFMATTERS: Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
RESCUE ESES: Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial (Phase IV) - Coordination
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MABSOT: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NEUROSIS Ť Neonatal European Study of Inhaled Steroids ť: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (Phase III)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the deltaF508 CFTR Mutation
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD - A double-blind, parallel group study
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
European Commission
DG Research - Directorate General for Research
BELGIEN
VLAAMS BRABANT
LEUVEN
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients
UZ Leuven - Campus Gasthuisberg
UZ Leuven
BELGIEN
VLAAMS BRABANT
LEUVEN
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients
UZ Leuven - Campus Gasthuisberg
UZ Leuven - Gasthuisberg
DANEMARK
Hovedstaden
COPENHAGEN
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
GAPVAC: Konsortium für die Entwicklung aktiv personalisierter Impfstoffe gegen Gliome
Immatics Biotechnologies GmbH
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
NEUROSIS Ť Neonatal European Study of Inhaled Steroids ť: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (Phase III)
Universitätsklinikum Tübingen
DEUTSCHLAND
Nordrhein-Westfalen
AACHEN
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia
Universitätsklinikum Aachen
FINNLAND
Finland
TURKU
TRAUMAKINE: Interferon-beta treatment of acute respiratory distress syndrome (ARDS)
Faron Pharmaceuticals Limited
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
EUROSARC: European Clinical trials in Rare Sarcomas within an integrated translational trial network
CLCC Léon Bérard
Centre Léon Bérard
FRANKREICH
ILE-DE-FRANCE
EVRY
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
Généthon
Centre de Recherche Généthon
FRANKREICH
ILE-DE-FRANCE
PARIS
GENEGRAFT: Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (Orphan drug designation (EU/3/09/630))
Hôpital Necker-Enfants Malades
Service de dermatologie
GRIECHENLAND
ATTIKI
MAROUSI
GRIECHENLAND
GREECE
ADDRESS: NOT PROVIDED - GR
Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis
Institution: Information not provided - GR
IRLAND
County Cork
CORK
CFMATTERS: Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
University College Cork
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND
IRLAND
County Dublin
DUBLIN
ITALIEN
CAMPANIA
NAPOLI
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Istituto Pascale
ITALIEN
CAMPANIA
NAPOLI
MeuSIX: Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder
TIGEM - Telethon Institute of Genetics and Medicine
Laboratorio di Ricerca
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Institution: Information not provided - IT
ITALIEN
MARCHE
URBINO
ITALIEN
SICILIA
ACI S. ANTONIO
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
Societŕ Industria Farmaceutica Italiana S.p.A.(S.I.F.I.)
ITALIEN
TOSCANA
SOVICILLE
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma
Philogen S.p.A. Localitŕ Bellaria n. 35
Philogen S.p.A.
NIEDERLANDE
Utrecht
UTRECHT
RESCUE ESES: Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial (Phase IV) - Coordination
UMC Utrecht - Universitair Medisch Centrum Utrecht
UMC Utrecht
NIEDERLANDE
Zuid-Holland
LEIDEN
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the deltaF508 CFTR Mutation
ProQR Therapeutics N.V.
NIEDERLANDE
Zuid-Holland
LEIDEN
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis
ProQR Therapeutics N.V.
OSTERREICH
STEIERMARK
GRAZ
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma
Medizinische Universität Graz
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Institution: Information not provided - SE
SCHWEDEN
Region Stockholm
STOCKHOLM
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Karolinska Universitetssjukhuset - Huddinge
Karolinska University Hospital - Huddinge
SCHWEDEN
Region Stockholm
STOCKHOLM
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Karolinska Universitetssjukhuset - Solna
Centre for Rare Diseases - Karolinska Universitetssjukhuset Solna
SCHWEDEN
Region Stockholm
STOCKHOLM
SCHWEDEN
Region Uppsala
UPPSALA
IMPACTT: Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment
Uppsala University
SCHWEIZ
Suisse Romande
PLAN-LES-OUATES
FIGHT-HLH: First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH
NovImmune SA
SCHWEIZ
Suisse Romande
PLAN-LES-OUATES
SPANIEN
Madrid
MADRID
EUROFANCOLEN: Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action
CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas
Terapias innovadoras en el sistema hematopoyético
VEREINIGTE STAATEN
Maryland
ROCKVILLE
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
ReveraGen BioPharma, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater London
LONDON
SKIP-NMD: A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53
GOSH NHS Foundatin Trust
Dubowitz Neuromuscular Centre
VEREINIGTES KONIGREICH
Greater London
LONDON
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
King's College London
King's College London Headquarters
VEREINIGTES KONIGREICH
Greater London
LONDON
VEREINIGTES KONIGREICH
Greater London
LONDON
EURO EWING Consortium - International Clinical Trials to Improve Survival from Ewing Sarcoma
University College Hospital
Joint Lymphoma Clinic, 1st Floor Central
VEREINIGTES KONIGREICH
Merseyside
LIVERPOOL
DEVELOPAKURE: Clinical Development of Nitisinone for Alkaptonuria
Royal Liverpool University Hospital NHS
The Robert Gregory Alkaptonuria Centre (NAC)
VEREINIGTES KONIGREICH
Merseyside
LIVERPOOL
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III)
Royal Liverpool University Hospital NHS
Linda McCartney Centre
VEREINIGTES KONIGREICH
Merseyside
LIVERPOOL
VEREINIGTES KONIGREICH
South Yorkshire
SHEFFIELD
TAIN: Treatment of Adrenal Insufficiency in neonates- Development of a Hydrocortisone Preparation for the treatment of Adrenal Insufficiency in neonatesand infants
TAIN Project, University of Sheffield
TAIN Project
VEREINIGTES KONIGREICH
Tyne & Wear
NEWCASTLE UPON TYNE
SCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine
VEREINIGTES KONIGREICH
West Midlands
BIRMINGHAM